296 related articles for article (PubMed ID: 34071152)
1. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand.
Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z
Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
[TBL] [Abstract][Full Text] [Related]
5. HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7.
Cao L; Li Q; Tong Z; Xing Y; Xu K; Yijia Wang J; Li W; Zhao J; Zhao L; Hong Z
Int J Pharm; 2020 Jan; 574():118939. PubMed ID: 31836485
[TBL] [Abstract][Full Text] [Related]
6. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.
Michalska M; Schultze-Seemann S; Bogatyreva L; Hauschke D; Wetterauer U; Wolf P
Oncotarget; 2016 Apr; 7(16):22531-42. PubMed ID: 26968813
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
9. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
[TBL] [Abstract][Full Text] [Related]
10.
Michalska M; Schultze-Seemann S; Kuckuck I; Wolf P
Anticancer Res; 2018 Jan; 38(1):61-69. PubMed ID: 29277757
[TBL] [Abstract][Full Text] [Related]
11. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
12. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
13. An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy.
Zhang F; Shan L; Liu Y; Neville D; Woo JH; Chen Y; Korotcov A; Lin S; Huang S; Sridhar R; Liang W; Wang PC
Adv Healthc Mater; 2013 May; 2(5):736-44. PubMed ID: 23184611
[TBL] [Abstract][Full Text] [Related]
14. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
Wolf P; Gierschner D; Bühler P; Wetterauer U; Elsässer-Beile U
Cancer Immunol Immunother; 2006 Nov; 55(11):1367-73. PubMed ID: 16547705
[TBL] [Abstract][Full Text] [Related]
15. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
[TBL] [Abstract][Full Text] [Related]
18. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
[TBL] [Abstract][Full Text] [Related]
19. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
20. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
[Next] [New Search]
